Loading
Biolargo, Inc.: what insiders have been doing
Biolargo, Inc., classified in the Chemicals sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Biolargo, Inc. logged 12 filings by 2 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Over the last twelve months, not one insider purchase of Biolargo, Inc. stock was filed. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 12 filings, this issuer sits below that mark.
For comparison within the same sector, see the insider buying recorded at Culp Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
29
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.08
Analyst consensus
1 analysts1.00/5
US$0.30Target US$0.30(+275%)US$0.30
Income statement
RevenueUS$7.8M
Gross profitUS$3.4M44% margin
EBITDA-US$14.2M-183% margin
Net income-US$11.8M-151.7% margin
Valuation
PER (forward)-2.7x
P/Book16.7x
Beta-0.12
Balance sheet & cash
Market capUS$26.3M
Total debtUS$3.5M
Free Cash Flow-US$8.3M
Profitability & ownership
ROE-1128.6%
ROA-118.1%
% insiders14.2%
% institutions0.0%
Last declaration on 2 October 2026
Declarations29 total
2,000,000 shares0Common StockSEC:0001437749-26-031944:1
566,261 shares@ US$0.080.17% mcap13.1% of flowCommon StockSEC:0001437749-26-031944:0
931,886 shares@ US$0.080.28% mcap28.7% of flowCommon StockSEC:0001437749-26-031943:0
2,000,000 shares0Common StockSEC:0001437749-26-031943:1
532,567 shares@ US$0.11350.20% mcap20.0% of flowCommon StockSEC:0001437749-26-022951:0
699,569 sharesCommon StockSEC:0001437749-26-022659:0
219,914 sharesCommon StockSEC:0001437749-26-022659:1
69,444 shares@ US$0.1623.7% of flowCommon StockSEC:0001437749-26-011170:0
54,803 shares@ US$0.18433.3% of flowCommon StockSEC:0001437749-26-000429:0
130,222 shares@ US$0.184312.5% of flowCommon StockSEC:0001437749-26-000421:0
313,754 shares@ US$0.1616.3% of flowCommon StockSEC:0001437749-25-035504:0
310,269 shares@ US$0.1626.1% of flowCommon StockSEC:0001437749-25-035493:0
169,498 shares@ US$0.2017.8% of flowCommon StockSEC:0001437749-25-022851:0
181,253 shares@ US$0.2011.8% of flowCommon StockSEC:0001437749-25-022850:0
57,666 shares@ US$0.194.0% of flowCommon stockSEC:0001437749-25-000351:0
72,621 shares@ US$0.1684.2% of flowCommon stockSEC:0001437749-24-000496:0
50,557 shares@ US$0.1684.7% of flowCommon stockSEC:0001437749-24-000493:0
19,010 shares@ US$0.16571.1% of flowCommon stockSEC:0001437749-23-027572:0
50,553 shares@ US$0.1795.0% of flowCommon stockSEC:0001437749-23-020751:0
68,541 shares@ US$0.1784.2% of flowCommon stockSEC:0001437749-23-019410:0
30,747 shares@ US$0.20492.2% of flowCommon stockSEC:0001437749-23-009344:0
167,781 shares@ US$0.2717.4% of flowCommon stockSEC:0001437749-22-023721:0
100,549 shares@ US$0.2716.9% of flowCommon stockSEC:0001437749-22-023722:0
156,111 shares@ US$0.1816.9% of flowCommon stockSEC:0001437749-22-016872:0
107,784 shares@ US$0.187.0% of flowCommon stockSEC:0001437749-22-016650:0
25 of 29 declarations
About Biolargo, Inc.
BioLargo, Inc. (ticker: BLGO) is a United States-based company with shares quoted on the OTCQX market; it is not listed on NYSE or NASDAQ, but it is often analyzed like a small-cap cleantech platform with a heavy emphasis on intellectual property and commercialization risk. The company is headquartered in Westminster, California, is incorporated in Delaware, and operates from several locations, including Westminster, Oak Ridge, Tennessee, Alberta in Canada, and Tampa, Florida. Its footprint reflects a business that combines environmental technologies, industrial products, and early-stage life sciences assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm))
BioLargo has built its strategy around developing, protecting, and commercializing proprietary technologies rather than competing as a broad industrial conglomerate. According to its SEC filings, the company reports six operating business segments plus corporate functions. The most visible businesses are ONM Environmental, which sells odor and volatile organic compound control products and related services; BioLargo Equipment Solutions & Technologies, which houses water-treatment solutions; Clyra Medical, its medical products unit; and additional technology efforts tied to energy and environmental applications. This structure gives BioLargo exposure to multiple end markets, but it also means investors should view the company as a portfolio of projects rather than a single mature operating franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm))
Read moreShow less
From a competitive standpoint, BioLargo positions itself as a niche innovator in environmental remediation and odor control. Its flagship commercial product, CupriDyne Clean, is used for industrial odor control, and the company describes it as the market’s number-one performing odor-control product. In water treatment, BioLargo’s Aqueous Electrostatic Concentrator (AEC) is designed to remove PFAS from water at lower operating cost and with less waste than common alternatives such as carbon filtration, ion exchange, and reverse osmosis. The company also references adjacent technologies such as AROS for water reuse and recycling, and AOS for micropollutant treatment and energy-efficient disinfection. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm))
Geographically, BioLargo remains primarily North American. Its California headquarters also houses manufacturing, while research and engineering capabilities are spread across Canada and Tennessee. On the healthcare side, Clyra Medical is based in Tampa, Florida. That geographic mix supports a cross-border R&D model, but it also underscores the company’s relatively modest scale and dependence on execution across several technically demanding programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm))
Recent developments have been especially important for the equity story. In 2025, BioLargo reported internal and third-party testing showing more than 99% removal of ultrashort-chain PFAS, including TFA, using its AEC technology. It also initiated alpha testing of a portable PFAS water test kit through Verralize. In February 2026, Clyra Medical received its first commercial stocking order for ViaCLYR, described as an FDA-cleared wound irrigation solution, marking an early revenue-generating milestone. In September 2025, BioLargo said it revoked a technology license granted to Pooph after contractual breaches and unpaid amounts, highlighting both the upside of technology licensing and the legal/collection risk that can accompany it. ([biolargo.com](https://www.biolargo.com/post/biolargo-demonstrates-over-99-removal-of-ultrashort-chain-pfas-including-tfa-using-aqueous-electros))
Overall, BioLargo should be viewed as a U.S. cleantech and life-sciences micro-cap with meaningful optionality, but also with high execution risk, ongoing commercialization needs, and a business model that still depends on converting technical validation into scalable revenue.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
